Budget 2023Budget 2023
you are here: HomeNewsOpinion

Gland Pharma’s streak of weak results should worry pharma investors

The stock’s valuation has compressed from around 40 times FY21 earnings to about 23 times the FY23 earnings estimated figure

January 25, 2023 / 09:35 AM IST
Gland Pharma’s streak of weak results should worry pharma investors

Highlights Annual revenues may drop for the first time since its listing The company is facing supply chain constraints for a year now with the issues yet to be resolved fully Competitive intensity increased in the US market and new products' scale-up is lagging expectations Growth rates may languish in the near term. New initiatives still in scale-up stage Gland Pharma’s revenue dropped for the third consecutive quarter in the December 2022 quarter, sending its shares to a new 52-week low on Tuesday. Revenue...

To read the full story, Subscribe to Moneycontrol PRO

Access the exclusive stories, weekly investment ideas and daily technical calls in an Ad free experience

Already a member? Sign in

Limited Period offer on Moneycontrol PRO. Subscribe to PRO and get up to

50% OFF

What Do You Get

  • Ad free experience

    Experience a non-intrusive navigation and faster response in the ad free mode

  • Sharpest Opinions

    Access to 230+ exclusive stories per month from our editorial and Experts

  • +

    Have a Global edge with access to content from world renowned experts and journalist

  • Actionable Insights

    Access to 40+ weekly investment ideas including 4 daily technical calls

  • Virtual Events

    Exclusive access to live webinars from market experts on trading and investment strategies

  • Newsletters

    Daily and weekly insights bundled and sent to your inbox to keep you ahead in the race.

Get upto 50% discount on limited period offers